Prospective validation of CD133 positivity as a marker for sarcoma CSCs in other sarcoma subtypes would need to be performed in the future and perhaps be combined with other assays for the identification and isolation of putative sarcoma CSCs. The gene discussed is PROM1; the disease is sarcoma.